Cost/benefit analysis of chlorhexidine-silver sulfadiazine-impregnated venous catheters for femoral access

Lorente, Leonardo; Lecuona, Marı́a; Jiménez, Alejandro; Lorenzo, L; Diosdado, Sara; Marca, Lucía; Mora, María L.

doi:10.1016/j.ajic.2014.06.027

Cited by 11 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Initially, we found that the use of rifampicin miconazole impregnated catheters could reduce CRBSI incidence and catheter related cost in the jugular venous access with tracheostomy and in the femoral venous access (22,23). Afterwards, we found that the use of second generation of CHSS catheters could reduce CRBSI incidence and catheter related cost in femoral venous access, jugular venous access and subclavian access (24)(25)(26). In the guidelines published in 2011 was recommended the use of antimicrobial/antiseptic impregnated catheters (CHSS or rifampicin-minocycline impregnated catheters) if the CRBSI rate has not decreased after implementation of a strategy based in basic preventive measures (which include education, the use of a >0.5% chlorhexidine preparation with alcohol for skin antisepsis, and the use of maximal sterile barrier precautions) (1).…”

mentioning

confidence: 99%

“…In respect to another measure for the prevention of CRBSI, such the use of antimicrobial/antiseptic impregnated catheters, our team has published the efficacy and efficiency of rifampicin-miconazole impregnated catheters and chlorhexidine-silver sulfadiazine (CHSS) impregnated catheters in different clinical circumstances (21)(22)(23)(24)(25)(26)(27). Different antimicrobial agents have been used for the impregnation, such as CHSS, rifampicin-minocycline, and rifampicin-miconazole.…”

mentioning

confidence: 99%

“…However, in all those cost-effectiveness analyses was included the cost associated with the increase of hospital stay. To simply the cost-effectiveness analyses, our team has carried out several studies to compare the immediate catheter related cost (including only the cost of CVC, diagnosis of CRBSI and antimicrobials for the treatment of CRBSI, and avoiding the cost due to increased hospital stay) using antimicrobial or antiseptic impregnated catheters or standard catheters (22)(23)(24)(25)(26). Initially, we found that the use of rifampicin miconazole impregnated catheters could reduce CRBSI incidence and catheter related cost in the jugular venous access with tracheostomy and in the femoral venous access (22,23).…”

mentioning

confidence: 99%

See 2 more Smart Citations

What is new for the prevention of catheter-related bloodstream infections?

Lorente

2016

Ann. Transl. Med.

Self Cite

View full text Add to dashboard Cite

After the publication in 2011 of latest guidelines of the Centers for Disease Control and Prevention (CDC) for the prevention of catheter-related bloodstream infections (CRBSI) some interesting findings have been published in that field. There has been published that skin disinfection with chlorhexidine alcohol reduced the risk of CRBSI compared to skin disinfection with povidone iodine alcohol, that the implementation of quality improvement interventions reduced the incidence of CRBSI, that the use of chlorhexidine impregnated dressing compared to standard dressings reduced the risk of CRBSI and catheter related cost in an health economic model, and that the use of antimicrobial/antiseptic impregnated catheters reduced the incidence of CRBSI and catheter related cost in clinical studies.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

What is new for the prevention of catheter-related bloodstream infections?

Lorente

2016

Ann. Transl. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Em seis estudos (11)(12)15,17,19,22) , o custo médio por episódio de IPCS foi inferior aos demais, variando entre €7,28 (12) e €1772 (17) , (28) . …”

Section: Métodounclassified

Custos Da Infecção Primária De Corrente Sanguínea Em Adultos: Revisão Integrativa

Danski

Pedrolo

Boostel

et al. 2017

Rev. baiana enferm.

View full text Add to dashboard Cite

Como citar este artigo: Danski MTR, Pedrolo E, Boostel R, Wiens A, Felix JVC. Custos da infecção relacionada a cateter venoso central em adultos: revisão integrativa. Rev baiana enferm 2017;31(3):e22079.Objetivo: conhecer o impacto financeiro da infecção primária de corrente sanguínea para as organizações hospitalares. Método: revisão integrativa desenvolvida nas bases de dados LILACS e EMBASE com MEDLINE, publicadas entre jun/2005 e jun/2015 com os descritores: cateteres venosos centrais, infecções relacionadas a cateter e custos e análises de custos. Resultados: foram elencadas 13 publicações e houve predomínio de estudos de coorte retrospectiva, desenvolvidos na Europa ou Estados Unidos com pacientes críticos. O custo para um episódio de infecção variou de $24.090 até $34.544. Estudos europeus encontraram valores entre €16.814 e €29.909. A infecção aumentou os dias de internação entre 1,5 e 26 dias, e a mortalidade entre 1,8% e 34%. Conclusão: as infecções relacionadas ao cateter representaram um custo elevado para as organizações hospitalares e, devido à discrepância entre os valores em diferentes países, há necessidade de avaliar o custo em cada realidade.

show abstract

“…The cost associated to CRBSI was approximately $10000 [18,24,25] ; however, this cost in some studies was as high as $40000 [5] and $71000 [7] due to hospital stay increase. To simply the cost-effectiveness analyses, our team carried out several studies to compare the costs associated with CVC using antimicrobial impregnated catheters or standard catheters (including only the cost related to the diagnosis of CRBSI, the antimicrobials used for the treatment of CRBSI, and avoiding the cost due to increased hospital stay) [26][27][28][29][30][31] . Initially, we carried out performed one study to analyze the efficacy of rifampicin-miconazole (RM) impregnated catheters to decrease the CRBSI risk [26] .…”

Section: Impregnated Cathetersmentioning

confidence: 99%

Antimicrobial-impregnated catheters for the prevention of catheter-related bloodstream infections

Lorente

2016

WJCCM

Self Cite

View full text Add to dashboard Cite

Central venous catheters are commonly used in critically ill patients. Such catheterization may entail mechanical and infectious complications. The interest in catheterrelated infection lies in the morbidity, mortality and costs that it involved. Numerous contributions have been made in the prevention of catheter-related infection and the current review focuses on the possible current role of antimicrobial impregnated catheters to reduce catheter-related bloodstream infections (CRBSI). There is evidence that the use of chlorhexidine-silver sulfadiazine (CHSS), rifampicin-minocycline, or rifampicin-miconazol impregnated catheters reduce the incidence of CRBSI and costs. In addition, there are some clinical circumstances associated with higher risk of CRBSI, such as the venous catheter access and the presence of tracheostomy. Current guidelines for the prevention of CRBSI recommended the use of a CHSS or rifampicin-minocycline impregnated catheter in patients whose catheter is expected to remain in place > 5 d and if the CRBSI rate has not decreased after implementation of a comprehensive strategy to reduce it.

show abstract

Cost/benefit analysis of chlorhexidine-silver sulfadiazine-impregnated venous catheters for femoral access

Cited by 11 publications

References 29 publications

What is new for the prevention of catheter-related bloodstream infections?

What is new for the prevention of catheter-related bloodstream infections?

Custos Da Infecção Primária De Corrente Sanguínea Em Adultos: Revisão Integrativa

Antimicrobial-impregnated catheters for the prevention of catheter-related bloodstream infections

Contact Info

Product

Resources

About